Millennium Clinical Trials | Thousand Oaks, CA

Research site

(Unclaimed)

Location

550 Saint Charles Drive, Suite 208, Thousand Oaks, California, United States of America

Site insights

Top conditions

Top treatments

Secukinumab

Upadacitinib

LY3502970

SM04690

PF-06700841

Deudomperidone

Linaclotide

Ianalumab

fezolinetant

CIN-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 26 total trials

A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus (GALACELA)

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Active, not recruiting

Systemic Lupus Erythematosus

Drug: GLPG3667

Drug: Placebo

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Tirzepatide

A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week trial of a formulation of AMZ001 once daily versus placeb...

Enrolling

Osteoarthritis of Knee

Osteoarthritis, Knee

Drug: Placebo gel

Drug: AMZ001 Diclofenac gel

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling

Diabetic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg or 10mg

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (M...

Active, not recruiting

COVID-19 Infection

Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

Drug: Placebo Administration

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneou...

Enrolling

Systemic Lupus Erythematosus

Drug: Placebo

Drug: Ianalumab

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) f...

Active, not recruiting

Polymyalgia Rheumatica

Drug: Secukinumab 150 mg

Other: Placebo to secukinumab

Locations recently updated

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling

Rheumatoid Arthritis

Drug: Adalimumab

Drug: Upadacitinib